Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Dime Community Bancshares Q2 revenue hits record on loan growth

Dime Community Bancshares Q2 revenue hits record on loan growth

ReutersReuters2026/07/23 11:13
By:Reuters


Overview

  • US regional bank's Q2 revenue hit record on net interest margin expansion and loan growth

  • Adjusted diluted EPS for Q2 rose to $0.79 from $0.64 a year earlier

  • Company plans to resume share buybacks in Q3, citing strong capital position


Outlook

  • Dime expects to resume share buybacks in the third qtr

  • Company anticipates loan repricing opportunities to continue through 2027

  • Growth in core deposits and business loans expected to benefit results over time


Result Drivers

  • NET INTEREST MARGIN EXPANSION - Co said higher net interest margin was a key driver of record Q2 revenue

  • BUSINESS LOAN GROWTH - Co cited strong growth in business loans as a major contributor to Q2 results

  • CORE DEPOSIT GROWTH - Co reported substantial year-over-year growth in core deposits, supporting funding and margin


Company press release: ID:nGNX6Mb1c3


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Net Income

$34.81 mln

Q2 Net Interest Income

$115.19 mln

Q2 Net Interest Margin (%)

3.28%


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the banks peer group is "buy"

  • Wall Street's median 12-month price target for Dime Commercial Bancshares Inc is $46.00, about 16.6% above its July 22 closing price of $39.46

  • The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 9 three months ago


Reuters Recommended Reads

  • July 20 - ServisFirst Bancshares Q2 EPS rises 40% on loan growth, higher net interest margin

  • July 23 - Huntington Bancshares Q2 net income rises 39% sequentially on loan growth

  • July 21 - KeyCorp quarterly profit rises on interest income strength


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The "Outlier" Investment Art in the New Era of Berky

他山之石观投资2026/09/14 09:22
The "Outlier" Investment Art in the New Era of Berky

Chevron (CVX.US) explores alternative hedging for Middle East supply disruptions: targets Argentina and the Mediterranean to drive global LNG growth, seeks deal with India

Chevron is focusing on Argentina and the Mediterranean region, seeking global growth in liquefied natural gas, and plans to reach an agreement with India.

智通财经2026/09/14 09:12
Chevron (CVX.US) explores alternative hedging for Middle East supply disruptions: targets Argentina and the Mediterranean to drive global LNG growth, seeks deal with India

Energy and food price pressures intensify, potentially triggering an inflation rebound! The Bank of England may struggle to remain "calm" as market rate hike bets surge

The upward pressure on energy prices caused by the unresolved Middle East war is mounting. New risks are also approaching, which may keep inflation above the Bank of England’s 2% target for most of next year.

智通财经2026/09/14 08:57
Energy and food price pressures intensify, potentially triggering an inflation rebound! The Bank of England may struggle to remain "calm" as market rate hike bets surge

AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales

Bloomberg Intelligence analyst John Murphy stated that the setback in AstraZeneca's breast cancer drug trial could reduce sales in 2035 by $2.6 billion to $3.8 billion.

智通财经2026/09/14 08:41
AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales